Efficacy and safety of secukinumab in the treatment of moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled phase II dose‐ranging study

Background  Conventional systemic therapies for plaque psoriasis have not fully met the needs of patients, and although current biologic treatments are generally well tolerated, concerns exist with respect to long‐term safety. Interleukin (IL)‐17A is believed to be an important effector cytokine in the pathogenesis of psoriasis and is produced by Th17 cells, a class of helper T cells that act outside the established Th1/Th2 paradigm for regulation of innate and adaptive immunity.

[1]  J. Ortonne,et al.  Secukinumab induction and maintenance therapy in moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled, phase II regimen‐finding study , 2012, The British journal of dermatology.

[2]  Subhashis Banerjee,et al.  Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. , 2012, The New England journal of medicine.

[3]  J. Ortonne,et al.  Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. , 2012, The New England journal of medicine.

[4]  V. Jala,et al.  Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. , 2011, Immunity.

[5]  A. Kimball,et al.  Latitude and psoriasis prevalence. , 2011, Journal of the American Academy of Dermatology.

[6]  S. Chimenti,et al.  Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. , 2011, The Journal of investigative dermatology.

[7]  P. Tak,et al.  Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis , 2010, Science Translational Medicine.

[8]  Pilar Romero,et al.  IL‐17‐producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17‐related cytokines , 2009, Journal of leukocyte biology.

[9]  Frank O. Nestle,et al.  Mechanisms of Disease: Psoriasis. , 2009 .

[10]  Lisa C. Zaba,et al.  Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. , 2008, The Journal of investigative dermatology.

[11]  James G. Krueger,et al.  Pathogenesis and therapy of psoriasis , 2007, Nature.

[12]  S. Sa,et al.  The Effects of IL-20 Subfamily Cytokines on Reconstituted Human Epidermis Suggest Potential Roles in Cutaneous Innate Defense and Pathogenic Adaptive Immunity in Psoriasis , 2007, The Journal of Immunology.

[13]  Ying Wang,et al.  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 , 2005, Nature Immunology.

[14]  R. D. Hatton,et al.  Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.

[15]  R. Stern,et al.  Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. , 2005, Journal of the American Academy of Dermatology.

[16]  T Fredriksson,et al.  Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.